Following a limited submission
AWMSG advice |
|||
| Status: Recommended | |||
Adalimumab (Humira®) is recommended as an option for use within NHS Wales for the treatment of paediatric chronic non-infectious anterior uveitis in patients from two years of age who have had an inadequate response to or are intolerant to conventional therapy, or in whom conventional therapy is inappropriate. |
|||
|
|||
Medicine details |
|||
| Medicine name | adalimumab (Humira®) | ||
| Formulation | 40 mg solution for injection | ||
| Reference number | 3035 | ||
| Indication | Treatment of paediatric chronic non-infectious anterior uveitis in patients from two years of age who have had an inadequate response to or are intolerant to conventional therapy, or in whom conventional therapy is inappropriate |
||
| Company | AbbVie Ltd | ||
| BNF chapter | Eye | ||
| Submission type | Limited | ||
| Status | Recommended | ||
| Advice number | 2717 | ||
| NMG meeting date | 01/11/2017 | ||
| AWMSG meeting date | 06/12/2017 | ||
| Date of issue | 08/12/2017 | ||
| Date of last review | December 2020 | ||